Supplementary material

Supplementary Table

Supplementary Table 1 Patient characteristics of transfused and non-transfused patients (30 days before IT start)

|                                | total (N = 55), n (%) | RBC transfusion (N = 9), n (%) | no RBC transfusion (N = 46), n (%) | p-value<sup>a</sup> |
|--------------------------------|-----------------------|-------------------------------|-----------------------------------|---------------------|
| **age (years)**                |                       |                               |                                   |                     |
| mean                           | 62                    | 55                            | 64                                | 0.094*              |
| range                          | 34-90                 | 35-76                         | 34-90                             |                     |
| elderly (>70)                  | 15 (27.3)             | 2 (22.2)                      | 13 (28.3)                         | 1.000               |
| **gender**                     |                       |                               |                                   |                     |
| male                           | 39 (70.9)             | 7 (77.8)                      | 32 (69.6)                         | 1.000               |
| female                         | 16 (29.1)             | 2 (22.2)                      | 14 (30.4)                         |                     |
| **ECOG**                       |                       |                               |                                   | 1.000               |
| 0-1                            | 35 (63.6)             | 6 (66.7)                      | 29 (63.0)                         |                     |
| ≥2                             | 17 (30.9)             | 3 (33.3)                      | 14 (30.4)                         |                     |
| **primarius**                  |                       |                               |                                   | 0.421               |
| lung                           | 19 (34.5)             | 3 (33.3)                      | 16 (34.8)                         |                     |
| skin                           | 7 (12.7)              | 0 (0)                         | 7 (15.2)                          |                     |
| head neck                      | 10 (18.2)             | 3 (33.3)                      | 7 (15.2)                          |                     |
| urogenital                     | 5 (9.1)               | 0 (0)                         | 5 (10.9)                          |                     |
| CUP                            | 4 (7.3)               | 0 (0)                         | 4 (8.7)                           |                     |
| breast                         | 3 (5.5)               | 1 (11.1)                      | 2 (4.3)                           |                     |
| others                         | 7 (12.7)              | 2 (22.2)                      | 5 (10.9)                          |                     |
| **one drug immunotherapy**     |                       |                               |                                   | 1.000               |
| Atezolizumab                   | 8 (14.5)              | 3 (33.3)                      | 5 (10.9)                          |                     |
| Pembrolizumab/Nivolumab        | 34 (61.8)             | 4 (44.4)                      | 30 (65.2)                         |                     |
| Ipilimumab                     | 1 (1.8)               | 0 (0)                         | 1 (2.2)                           |                     |
| **two drug immunotherapy**     |                       |                               |                                   |                     |
| Nivolumab+Ipilimumab           | 12 (21.8)             | 2 (22.2)                      | 10 (21.7)                         |                     |
| **additional therapy**         |                       |                               |                                   |                     |
| additional chemotherapy        | 15 (27.3)             | 4 (44.4)                      | 11 (23.9)                         | 0.236               |
| additional radiotherapy        | 11 (20.0)             | 3 (33.3)                      | 8 (17.4)                          | 0.362               |
| **line of therapy**            |                       |                               |                                   | 0.166               |
| 1                              | 14 (25.5)             | 3 (33.3)                      | 11 (23.9)                         |                     |
| 2                              | 15 (27.3)             | 0 (0)                         | 15 (32.6)                         |                     |
| 3                              | 13 (23.6)             | 4 (44.4)                      | 9 (19.6)                          |                     |
| 4                              | 5 (9.1)               | 1 (11.1)                      | 4 (8.7)                           |                     |
| ≥5                             | 8 (14.5)              | 1 (11.1)                      | 7 (15.2)                          |                     |
| mean                           | 2.7                   | 2.7                           | 2.7                               |                     |
| **number of organs with metastasis** |                     |                               |                                   | 0.070*              |
| mean                           | 1.7                   | 2.3                           | 1.7                               |                     |
| **LDH**                        |                       |                               |                                   | 0.051*              |
| mean                           | 317                   | 704                           | 238                               |                     |

<sup>a</sup>was calculated using Fisher's exact/*Wilcoxon

RBC = red blood cell, CUP = cancer of unknown primary